艾地苯醌联合尼麦角林治疗慢性脑缺血头晕患者的疗效及对患者氧化应激的影响<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2021.04.002

摘要
图/表
参考文献(11)
相关文章 (15)

全文: PDF (1162 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 【目的】 探讨艾地苯醌联合尼麦角林治疗慢性脑缺血头晕患者的疗效及对患者氧化应激的影响。【方法】 128例慢性脑缺血头晕患者随机分为观察组与对照组,对照组应用艾地苯醌治疗,观察组应用艾地苯醌联合尼麦角林治疗。比较两组患者临床疗效及治疗前后血清中炎性因子[肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、IL-23]、神经细胞因子[脑源性神经营养因子(BDNF)、神经生长因子(NGF)]、氧化应激因子[一氧化氮(NO)、超氧化物歧化酶(SOD)、丙二醛(MDA)]水平的变化。【结果】 治疗后观察组患者临床疗效明显好于对照组(P<0.05)。治疗前两组患者血清中各项相关因子比较差异均无显著性(P>0.05);观察组患者TNF-α、IL-6、IL-23炎性因子水平均低于对照组(P<0.05);BDNF、NGF等神经细胞因子水平显著高于对照组(P<0.05);治疗后观察组NO、MDA水平低于对照组,SOD水平高于对照组(P<0.05)。【结论】 艾地苯醌联合尼麦角林治疗慢性脑缺血头晕患者,可改善患者氧化应激因子水平,提升临床疗效,降低炎性因子水平,提高神经细胞因子含量,其疗效满意,值得应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李晶
	张妮

关键词 ：脑缺血发作, 短暂性/药物疗法, 麦角林类/治疗应用, 泛醌/治疗应用, 氧化性应激

Abstract：【Objective】 To investigate the effect of aldibenzoquinone combined with Nimergoline on oxidative stress in patients with chronic cerebral ischemia dizziness. 【Methods】 A total of 128 patients with chronic cerebral ischemia dizziness were randomly divided into two groups. The control group was treated with aldibenzoquinone, while the observation group was treated with aldibenzoquinone combined with nimergoline. The levels of inflammatory cytokines (TNF-α, IL-6 and IL-23), never cytokine (BDNF and NGF) in serum and oxidative stress factors (NO, SOD and MDA) before and after treatment were compared between the two groups. 【Results】 There were no significant differences in all factors between the two groups before treatment (P>0.05). After treatment, the clinical efficacy of the observation group was significantly better than that of the control group (P<0.05). The levels of TNF-α, IL-6 and IL-23 inflammatory factors in the observation group were lower than those in the control group (P<0.05). The clinical treatment effect of the observation group was significantly better than that of the control group (P<0.05). The levels of nerve cytokines such as BDNF and NGF in the observation group after treatment were significantly higher than those in the control group (P<0.05). The levels of NO and MDA in the observation group were lower than those in the control group, while the level of SOD was higher than that in the control group (P<0.05). 【Conclusion】 The treatment of chronic cerebral ischemia dizziness patients with aldibenzoquinone combined with nimergoline can improve the level of oxidative stress factor, improve the clinical treatment effect, reduce the level of inflammatory factor and improve the content of nerve cytokines. The clinical effect is satisfactory and it is worthy of application.

Key words： Ischemic Attack, Transient/DT Ergolines/TU Ubiquinone/TU Oxidative Stress

收稿日期: 2019-04-04

中图分类号:

R743.31

基金资助:* 国家自然科学基金项目(81100985)

通讯作者: ** E-mail:shanxizhangni@163.com

引用本文:

李晶, 张妮. 艾地苯醌联合尼麦角林治疗慢性脑缺血头晕患者的疗效及对患者氧化应激的影响^*[J]. 医学临床研究, 2021, 38(4): 484-487.
LI Jing, ZHANG Ni. Effects of Aldibenzoquinone Combined with Nierergerine on Oxidative Stress in Patients with Chronic Cerebral Ischemia Dizziness. JOURNAL OF CLINICAL RESEARCH, 2021, 38(4): 484-487.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.04.002 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I4/484

[1] 慢性脑供血不足与其交叉性小脑神经机能联系不能的CT灌注成像分析[J].中华医学杂志,2017,16(5):325-326.
[2] 孔祥溢,关健,王任直.氧化应激在急性脑缺血病程中的分子生物学作用[J].中国医学科学院学报,2016,38(2):222-227.
[3] EDRISSI H,SCHOCK SC,HAKIM AM,et al. Microparticles generated during chronic cerebral ischemia increase the permeability of microvascular endothelial barriers in vitro[J].Brain Res,2016, 16(34):83-85.
[4] 黄丹,屈云.缺血后处理对脑缺血保护作用的实验研究进展[J].中国康复医学杂志,2017,32(5):164-168.
[5] 张申,赵丹鹏,刘扬,等.艾地苯醌对缺血性脑卒中后抑郁患者血清神经细胞因子、单胺类递质代谢及炎症反应的影响[J].中国老年学杂志,2016,36(15):3709-3710.
[6] CAO Y, LIANG L,XU J,et al. The effect of Scutellaria baicalensis stem-leaf flavonoids on spatial learning and memory in chronic cerebral ischemia-induced vascular dementia of rats[J].Acta Biochimica Et Biophysica Sinica,2016, 48(5):437-438.
[7] LI C,SUN H,ARRICK D M,et al. Chronic nicotine exposure exacerbates transient focal cerebral ischemia-induced brain injury[J].J Appl Physiol,2016, 120(3):328-333.
[8] 郝敏锋,任秀,郭生龙,等.尼麦角林治疗认知障碍疗效的Meta分析[J].山西医科大学学报,2017,14(5):79-84.
[9] 裴裴,卫汨.尼麦角林联合舒血宁注射液治疗眩晕症的临床效果及对TCD参数的影响[J].中国医药导报,2018,11(8):213-214.
[10] CUARTERO M I,DE LA PARRA J,GARCÍA-CULEBRAS A, et al. The kynurenine pathway in the acute and chronic phases of cerebral ischemia[J].Curr Pharm Des,2016, 22(8):1060-1073.
[11] 周立,杜林,吴克礼,等.尼麦角林对缺血性脑卒中后认知障碍及血清脑源性神经营养因子、神经生长因子和神经元特异性烯醇化酶的影响[J].血栓与止血学,2017,23(5):729-732.